<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pregnancy and valve disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pregnancy and valve disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pregnancy and valve disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Candice Silversides, MD, MS, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H10779040"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemodynamic changes during pregnancy, including increases in heart rate, stroke volume, and cardiac output (see  <a class="medical medical_review" href="/z/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a>), can result in cardiac decompensation in women with valvular heart disease (VHD). Stenotic valve lesions are generally less well tolerated during pregnancy compared with regurgitant lesions. The risk of complications varies according to the type and severity of the underlying VHD.</p><p>This topic will discuss risk assessment and management of native valve disease during pregnancy. Evaluation and management of pregnant women with bicuspid aortic valve, with mitral stenosis, with Marfan syndrome, and with prosthetic heart valves are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/8133.html" rel="external">"Pregnancy in women with mitral stenosis"</a> and  <a class="medical medical_review" href="/z/d/html/8129.html" rel="external">"Heritable thoracic aortic diseases: Pregnancy and postpartum care"</a> and  <a class="medical medical_review" href="/z/d/html/8126.html" rel="external">"Management of antithrombotic therapy for a prosthetic heart valve during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H10779046"><span class="h1">PRECONCEPTION OR INITIAL EVALUATION</span></p><p class="headingAnchor" id="H505124144"><span class="h2">Timing</span><span class="headingEndMark"> — </span>When possible, women should undergo preconception assessment and counseling so that they are able to make informed pregnancy decisions. For women who have not had preconception counseling, a complete risk evaluation should occur at the first antenatal visit.</p><p>In developed health care systems, women are often aware of significant health conditions in advance of pregnancy; however, occasionally, pregnancy unmasks a previously unrecognized valve lesion. This latter scenario may be more frequent in developing health care systems, for instance in women with undiagnosed rheumatic mitral stenosis who first present during pregnancy.</p><p>In general, there are many health outcome benefits to seeking preconception counseling. Women with valvular heart disease (VHD) should have a preconception evaluation by a cardiologist with expertise in pregnancy and VHD [<a href="#rid1">1</a>]. Risk assessment for women with VHD should involve a focused evaluation of the risk for the mother and baby. Many women with heart disease are unaware of the risks of pregnancy, and patient education is an important aspect of the preconception assessment [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/448.html" rel="external">"The preconception office visit"</a>.)</p><p class="headingAnchor" id="H10779053"><span class="h2">Preconception evaluation</span><span class="headingEndMark"> — </span>Preconception (or initial if the patient presents during pregnancy) evaluation should include a detailed history, information on prior valve interventions (valvuloplasty, valvotomy, and surgical repairs/replacements), symptom status, a complete physical exam, a 12 lead electrocardiogram, a transthoracic echocardiogram, and an assessment of functional status. In patients presenting with valve disease, it is important to determine a cause such as a history of rheumatic fever or rheumatic heart disease, prior chest irradiation, systemic illness that can induce valvulitis, or a family history of VHD, congenital heart disease, aortopathy, or premature sudden cardiac death. (See  <a class="medical medical_review" href="/z/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults"</a>.)</p><p class="headingAnchor" id="H10779060"><span class="h2">Echocardiographic assessment</span><span class="headingEndMark"> — </span>A transthoracic echocardiogram is indicated in patients with known or suspected valve disease, preferably prior to conception [<a href="#rid1">1</a>]. The echocardiogram is important to determine the type and severity of valvular lesions, the degree of left or right ventricular dilation and/or dysfunction, and the presence of pulmonary hypertension or any other associated cardiac defects. In the setting of stenotic valve lesions, valve gradients may increase during pregnancy and should be interpreted accordingly. The severity of regurgitation may remain unchanged, increase, or decrease during pregnancy. Left ventricular (LV) systolic function is generally unchanged during pregnancy, though alterations in Doppler indices of ventricular function during normal pregnancy have been reported [<a href="#rid3">3</a>].</p><p>Cardiac magnetic resonance imaging as a risk stratification tool in pregnancy is most useful in women with VHD who have associated aortopathies (ie, women with Marfan syndrome or bicuspid valve-associated aortopathy) [<a href="#rid4">4-6</a>].</p><p class="headingAnchor" id="H10779067"><span class="h2">Exercise testing</span><span class="headingEndMark"> — </span>Exercise testing (with or without echocardiograms) or cardiopulmonary testing may aid risk assessment and can objectively estimate functional capacity, which is an important determinant of pregnancy outcome. An abnormal (blunted) chronotropic response to exercise has been associated with adverse outcomes in pregnancy in women with congenital heart disease [<a href="#rid7">7</a>]. Exercise testing is useful in women with severe asymptomatic aortic stenosis to quantify functional capacity and assess blood pressure response to exercise. In women with mitral stenosis who have symptoms out of proportion to the degree of valve stenosis, stress echocardiography can be helpful to examine changes in the right ventricular systolic pressure with exercise.</p><p class="headingAnchor" id="H10779074"><span class="h2">Biomarkers</span><span class="headingEndMark"> — </span>The utility of cardiac biomarkers for risk stratification in women with VHD considering pregnancy has not been determined. Elevated levels of natriuretic peptides are reported during uncomplicated pregnancies of women with established heart disease, making interpretation more complicated [<a href="#rid8">8,9</a>]. Normal levels of natriuretic peptides are useful in excluding cardiac decompensation in pregnancy [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H10779081"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Review of current medication use and dose will inform a discussion between the practitioner and patient on the benefits and risks of medication use in pregnancy. Some cardiac medications (eg, angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers) will need to be discontinued or substituted with an alternative drug if they are teratogenic or pose a risk for the developing fetus.</p><p class="headingAnchor" id="H10779088"><span class="h1">INTERVENTIONS PRIOR TO PREGNANCY</span><span class="headingEndMark"> — </span>Some women with high-risk valvular heart disease (VHD) may require intervention prior to pregnancy to minimize risks or may be advised to avoid pregnancy [<a href="#rid1">1,10,11</a>]. High-risk lesions include severe symptomatic or asymptomatic mitral stenosis and severe symptomatic aortic stenosis [<a href="#rid1">1,11</a>].</p><p>Patients referred for valve intervention prior to possible pregnancy should receive prepregnancy counseling by a cardiologist with expertise in managing patients with VHD during pregnancy. This review should include a discussion of the risks and benefits of all options for transcatheter or surgical intervention, including mechanical prosthesis, bioprosthesis, the Ross procedure, and valve repair [<a href="#rid1">1</a>]. For those women requiring a valve replacement, the choice of prosthesis should be based on shared decision-making with the patient. Cardiac surgery should be avoided, if possible, during pregnancy. While the maternal risks are similar to those in nonpregnant women, cardiopulmonary bypass during pregnancy poses significant risk for the fetus [<a href="#rid12">12</a>].</p><p>Valve replacement prior to pregnancy raises complex issues and necessitates a detailed discussion on the risks and benefits of various valve options with the patient [<a href="#rid13">13</a>]. In brief, the trade-off involves the risk of pregnancy-related thromboembolic complications and the fetal risks of anticoagulant therapy (<a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is teratogenic) with mechanical valves versus the limited durability and need for reinterventions with bioprosthetic valves.</p><p class="bulletIndent1"><span class="glyph">●</span>Women with normal-functioning bioprosthetic heart valves who do not require anticoagulation generally tolerate pregnancy well. However, approximately 30 to 35 percent of heterograft prostheses and 10 to 20 percent of homograft prostheses fail within 10 to 15 years of implantation. Thus, women of childbearing age who have a bioprosthesis are likely to require at least one additional valve surgery during their lifetime. Although some early studies suggested that valve deterioration is accelerated during or shortly after pregnancy [<a href="#rid14">14-16</a>], subsequent reports have not confirmed this finding [<a href="#rid17">17-22</a>].</p><p></p><p class="bulletIndent1">For patients who require aortic valve replacement prior to pregnancy, replacement of the aortic valve by a pulmonary autograft (Ross procedure) by an experienced surgeon is a potential option [<a href="#rid1">1</a>]. However, patients undergoing the Ross procedure face a risk of aortic graft or right ventricular outflow tract reoperation of 15 percent at 25 years [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/8143.html" rel="external">"Choice of prosthetic heart valve for surgical aortic or mitral valve replacement", section on 'Ross procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of pregnancy is high for both the mother and fetus when a mechanical valve is present, largely due to risk of valve thrombosis and thromboembolism and the need for anticoagulation to prevent these complications. All anticoagulants are associated with increased risk of miscarriage  (<a class="graphic graphic_table graphicRef115116" href="/z/d/graphic/115116.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a>, which is the most reliable anticoagulant for prevention of thromboembolic complications in pregnant women, is associated with a risk of fetal defects (warfarin embryopathy and fetopathy) as well as increased risk of fetal loss compared with low molecular weight heparin. On the other hand, <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> and low molecular weight heparin do not cross the placenta and are not teratogenic but are associated with increased risk of mechanical valve thrombosis and thromboembolism. Another potential complication includes bleeding secondary to anticoagulation. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8126.html" rel="external">"Management of antithrombotic therapy for a prosthetic heart valve during pregnancy"</a>.)</p><p></p><p>Because of these risks, it is preferable that women with moderate valvular disease and those who have undergone reparative surgery who are contemplating pregnancy <strong>not</strong> delay pregnancy. If possible, valve repair, instead of replacement, is preferred prior to pregnancy.</p><p>The alternative approaches for valve intervention prior to pregnancy vary with the valve lesion:</p><p class="bulletIndent1"><span class="glyph">●</span>Balloon valvotomy is preferred to valve replacement for patients with mitral stenosis with appropriate valvular anatomy. (See  <a class="medical medical_review" href="/z/d/html/8161.html" rel="external">"Percutaneous mitral balloon commissurotomy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Valve repair is the preferred surgical procedure in patients with mitral regurgitation with indications for valve surgery. If valve replacement is necessary, a bioprosthetic valve is usually recommended because long-term anticoagulation is not required (in the absence of atrial fibrillation). However, degeneration of bioprosthetic valves occurs after 10 to 15 years (depending upon the valve location); as a result, bioprosthetic valve replacement will be needed. (See  <a class="medical medical_review" href="/z/d/html/8138.html" rel="external">"Surgical procedures for severe chronic mitral regurgitation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic stenosis in young women is, in developed countries, almost always due to bicuspid aortic valve, and noncalcified severely stenotic bicuspid valves can sometimes be treated with percutaneous aortic balloon valvotomy rather than aortic valve replacement. (See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy", section on 'Aortic stenosis treatment prior to pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/129707.html" rel="external">"Bicuspid aortic valve: Intervention for valve disease or aortopathy in adults", section on 'Balloon valvotomy'</a> and  <a class="medical medical_review" href="/z/d/html/129707.html" rel="external">"Bicuspid aortic valve: Intervention for valve disease or aortopathy in adults"</a>.)</p><p></p><p class="headingAnchor" id="H10779095"><span class="h1">GENERAL APPROACH TO RISK STRATIFICATION</span><span class="headingEndMark"> — </span>Risk assessment should incorporate general risk factors relevant for all women with heart disease, lesion-specific risks as available, and patient-specific data such as exercise test results. Risk stratification will determine the frequency of clinical re-evaluation during pregnancy. Risk assessment and progress during pregnancy will also establish labor and delivery as well as postpartum plans.</p><p class="headingAnchor" id="H10779103"><span class="h2">Maternal cardiac risk predictors</span><span class="headingEndMark"> — </span>There are two frequently used general risk scores: the CARPREG (Cardiac Disease in Pregnancy) risk score and the ZAHARA (Zwangerschap bij vrouwen met een Aangeboren HARtAfwijking-II, translated as Pregnancy in women with congenital heart disease II) risk score. While neither of the risk scores were derived specifically for women with valve disease, they can be a helpful starting point for estimating cardiac risks during pregnancy. Risk assessment should incorporate general risk scores, lesion-specific information, and individual variables that may impact outcomes.</p><p>The CARPREG study was an observational prospective cohort study of 562 consecutive pregnant women (599 pregnancies) with acquired or congenital heart disease [<a href="#rid24">24,25</a>]. Four predictors of an adverse maternal cardiac event in pregnancy were identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Left heart obstruction (mitral valve area &lt;2 cm<sup>2</sup>, aortic valve area &lt;1.5 cm<sup>2</sup>, or peak LV outflow tract gradient &gt;30 mmHg) (1 point).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of a prior cardiac event (heart failure [HF], transient ischemic attack, or stroke) or arrhythmia (1 point).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor baseline New York Heart Association (NYHA) functional class (class 3 or 4) or cyanosis (1 point).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic ventricular systolic function &lt;40 percent (1 point).</p><p></p><p>A point is allocated for each risk factor identified, and the risk is then estimated on the basis of the total score. Pregnancies with 0, 1, and &gt;1 points had adverse cardiac event rates of 5, 27, and 62 percent, respectively [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Assessing risk'</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Maternal cardiovascular risk assessment'</a>.)</p><p>The CARPREG II study was an extension of the CARPREG study and included 1938 pregnancies from two large tertiary care centers [<a href="#rid26">26</a>]. Ten predictors of maternal cardiac complications were identified and incorporated into a weighted risk score with the following risk predictors:</p><p class="bulletIndent1"><span class="glyph">●</span>Five general predictors</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac events or arrhythmias prior to pregnancy (3 points)</p><p class="bulletIndent2"><span class="glyph">•</span>Baseline functional class (class 3 or 4) or cyanosis (3 points)</p><p class="bulletIndent2"><span class="glyph">•</span>High-risk valve disease and LV outflow tract obstruction (2 points)</p><p class="bulletIndent2"><span class="glyph">•</span>Systemic ventricular dysfunction (2 points)</p><p class="bulletIndent2"><span class="glyph">•</span>No prior cardiac interventions (1 points)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Four lesion-specific predictors</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical valves (3 points)</p><p class="bulletIndent2"><span class="glyph">•</span>High-risk aortopathies (2 points)</p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary hypertension (2 points)</p><p class="bulletIndent2"><span class="glyph">•</span>Coronary artery disease (2 points)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One delivery of care predictor</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late pregnancy assessment (1 points)</p><p></p><p>The predicted risk for maternal cardiac events in women with a point score of 0 to 1 points was 5 percent, 2 points was 10 percent, 3 points was 15 percent, 4 points was 22 percent, and &gt;4 points was 41 percent.</p><p>The ZAHARA score is based upon a retrospective observational cohort study of 1302 completed pregnancies in 714 women with exclusively congenital heart disease, including predominantly complicated lesions [<a href="#rid27">27</a>]. The ZAHARA risk score is derived from a weighted scoring system to predict adverse maternal cardiac events and includes the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical heart valve (4.25 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe left heart obstruction (mean pressure gradient &gt;50 mmHg or aortic valve area &lt;1.0 cm<sup>2</sup>) (2.50 points)</p><p class="bulletIndent1"><span class="glyph">●</span>History of arrhythmias (1.50 points)</p><p class="bulletIndent1"><span class="glyph">●</span>History of cardiac medication use before pregnancy (1.50 points)</p><p class="bulletIndent1"><span class="glyph">●</span>History of cyanotic heart disease (uncorrected or corrected) (1.00 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate-to-severe pulmonary or systemic atrioventricular valve regurgitation (0.75)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic HF before pregnancy (NYHA class ≥II) (0.75 points)</p><p></p><p>The score is divided into five categories of risk based on accrued points: 0 to 0.5 points, 2.9 percent; 0.51 to 1.50 points, 7.5 percent; 1.51 to 2.50, 17.5 percent; 2.51 to 3.50, 43.1 percent; and &gt;3.51, 70.0 percent risk, respectively.</p><p>A retrospective single-center study identified the presence of right ventricular systolic dysfunction and/or severe pulmonic regurgitation as additional independent risk factors for adverse events [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H10779116"><span class="h2">Fetal and neonatal risk predictors</span><span class="headingEndMark"> — </span>In women with heart disease, including those with valvular heart disease, fetal and neonatal complications have been reported to occur in as many as 25 percent of the pregnancies [<a href="#rid29">29,30</a>]. Fetal and neonatal complications include preterm delivery, intrauterine growth restriction, reduced birth weight, respiratory distress syndrome, intraventricular hemorrhage, and death. Maternal predictors of fetal and neonatal complications include [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Left heart obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical heart valves</p><p class="bulletIndent1"><span class="glyph">●</span>Poor baseline NYHA functional class (class 3 or 4) or cyanosis</p><p class="bulletIndent1"><span class="glyph">●</span>Use of anticoagulation during pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking during pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple gestation</p><p class="bulletIndent1"><span class="glyph">●</span>Extremes of age (&lt;20 and &gt;35 years)</p><p></p><p>The heritability of congenital heart disease should be discussed. Offspring of affected parents are at increased risk of congenital heart disease. The risk of recurrent congenital heart disease (with a lesion same as or different from the parents) varies depending upon the specific defect and genetic predisposition. (See  <a class="medical medical_review" href="/z/d/html/1415.html" rel="external">"Pregnancy in women with congenital heart disease: Specific lesions"</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Inheritance'</a>.)</p><p class="headingAnchor" id="H10779137"><span class="h1">LESION SPECIFIC RISKS AND MANAGEMENT</span><span class="headingEndMark"> — </span>In addition to the general risk predictors discussed above, lesion-specific risks should be factored into this assessment [<a href="#rid1">1,11</a>]. Most women with mild forms of valvular heart disease (VHD) will do well throughout pregnancy. Stenotic valve lesions are generally less well tolerated during pregnancy compared with regurgitant lesions but either can lead to decompensation.</p><p class="headingAnchor" id="H505126849"><span class="h2">Modified WHO classification</span><span class="headingEndMark"> — </span>The Working Group on Pregnancy and Contraception classified pregnancy risk in women with heart disease using modified World Health Organization (WHO) classification categories [<a href="#rid32">32</a>]. The modified WHO classification of pregnancy risk for VHD and some conditions associated with valve disease are specified in the 2018 European Society of Cardiology guidelines for management of cardiovascular disease during pregnancy [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Modified WHO risk class I conditions are associated with no detectable increased risk of maternal mortality and no/mild increase in morbidity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valve conditions in this category include mild pulmonic stenosis and mitral valve prolapse. Cardiology follow-up during pregnancy may be limited to one or two visits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modified WHO risk class II conditions are associated with small increased risk of maternal mortality or moderate increase in morbidity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valve conditions in risk class II include repaired tetralogy of Fallot. These women often have residual pulmonic regurgitation or stenosis. Follow-up every trimester is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modified WHO risk class II to III conditions are associated with significantly increased risk of maternal mortality or moderate to severe increased risk of morbidity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valve conditions in risk class II to III include native or tissue VHD not considered WHO I or IV and bicuspid aortic valve with ascending aorta diameter &lt;45 mm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modified WHO risk class III conditions are associated with significantly increased risk of maternal mortality or severe morbidity. Expert counseling is required and this may include consideration of alternatives to pregnancy. Intensive specialist cardiac and obstetric monitoring are needed throughout pregnancy, childbirth, and the puerperium. Monthly or bimonthly cardiology and obstetric follow-up during pregnancy are recommended at a minimum.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valve conditions in this category include a mechanical valve, moderate mitral stenosis, severe asymptomatic aortic stenosis, and bicuspid aortic valve with ascending aortic diameter of 45 to 50 mm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modified WHO risk class IV conditions are associated with extremely high risk of maternal mortality or severe morbidity; pregnancy is contraindicated. If a woman presents with a lesion in this class early in pregnancy, termination should be discussed. If pregnancy is terminated, appropriate intervention for high-risk valve and/or aortic disease should be performed before another attempt at pregnancy (see <a class="local">'Interventions prior to pregnancy'</a> above). If pregnancy continues, care as for class III with monthly or bimonthly cardiology and obstetric follow-up at a minimum.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conditions in this category include severe mitral stenosis, severe symptomatic aortic stenosis, bicuspid aortic valve with ascending aorta diameter &gt;50 mm, severe systemic ventricular systolic dysfunction (LV ejection fraction [LVEF] &lt;30 percent, New York Heart Association [NYHA] III to IV), and pulmonary arterial hypertension.</p><p></p><p class="headingAnchor" id="H505126855"><span class="h2">Specific lesions</span></p><p class="headingAnchor" id="H10779144"><span class="h3">Aortic stenosis</span><span class="headingEndMark"> — </span>The most common cause of aortic stenosis among women of childbearing age is congenital bicuspid aortic valve disease [<a href="#rid33">33-35</a>]. Aortic stenosis due to rheumatic heart disease is an uncommon cause and is generally accompanied by mitral stenosis. Pregnancy is usually well tolerated in patients with mild and moderate aortic stenosis, but patients with severe aortic stenosis tolerate the hemodynamic alterations of pregnancy poorly.</p><p>HF and atrial and ventricular arrhythmias are the common pregnancy complications reported in women with aortic stenosis and these occur most often in women with severe aortic stenosis [<a href="#rid29">29,33,34,36,37</a>]. In women with fixed outflow tract obstruction, the inability to accommodate to the increased cardiac output and stroke volume can increase the LV end diastolic pressure, precipitating pulmonary edema or arrhythmias. Maternal deaths and aortic dissection in women with bicuspid valve aortopathy are rare.</p><p>In a review of publications between 1985 and 2019 on pregnancy outcomes in women with aortic stenosis in medium or higher Human Development Index countries, rates of pulmonary edema and new or recurrent arrhythmias were 9 and 4 percent for women with severe aortic stenosis and 8 and 2 percent for women with moderate aortic stenosis. Maternal mortality for women with severe aortic stenosis was 2 percent [<a href="#rid37">37</a>].</p><p>High rates of obstetric and fetal/neonatal complications have been reported in women with significant aortic stenosis [<a href="#rid33">33,34,36</a>].</p><p>Aortic stenosis is staged according to valve anatomy, stenosis severity, LV geometry and function, and symptoms  (<a class="graphic graphic_table graphicRef95630" href="/z/d/graphic/95630.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. Patients with aortic stenosis should receive preconception counseling by a cardiologist experienced in managing VHD during pregnancy. Asymptomatic women with severe aortic stenosis require careful preconception assessment; blood pressure response to exercise can be helpful in risk stratification [<a href="#rid31">31</a>].</p><p>All women with symptomatic aortic stenosis should have a valve intervention prior to pregnancy.</p><p>If symptoms develop during pregnancy, restricted activities are a reasonable first step. Pulmonary edema should be treated with diuretics. Rarely, women with persistent symptoms despite medical therapy may need to be considered for a valve intervention (either valvuloplasty or aortic valve replacement) during pregnancy.</p><p>Risk assessment and management of pregnancy in women with aortic stenosis secondary to bicuspid aortic valve disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a>.)</p><p class="headingAnchor" id="H10779152"><span class="h3">Mitral stenosis</span><span class="headingEndMark"> — </span>The most common cause of mitral stenosis among women of childbearing age is rheumatic heart disease. Congenital heart disease (eg, parachute mitral valve) is a less common cause of mitral stenosis.</p><p>In women with moderate to severe mitral stenosis, the increased cardiac output and heart rate (decreased diastolic filling time) associated with pregnancy can result in increases in left atrial pressure leading to complications, including atrial fibrillation and pulmonary edema [<a href="#rid29">29,38,39</a>].</p><p>In a review of publications between 1985 and 2019 on pregnancy outcomes in women with mitral stenosis in medium or higher Human Development Index countries, rates of pulmonary edema and new or recurrent arrhythmias were 37 and 16 percent for women with severe mitral stenosis and 18 and 5 percent for women with moderate mitral stenosis [<a href="#rid37">37</a>]. Maternal mortality for women with severe mitral stenosis was 3 percent, and for women with moderate mitral stenosis it was 1 percent.</p><p>If severe mitral stenosis is recognized before pregnancy, percutaneous mitral balloon valvotomy is recommended if valve morphology is favorable for intervention [<a href="#rid40">40-42</a>].</p><p>Beta blockers are the mainstay of therapy for pregnant patients with mitral stenosis; they act by controlling heart rate and increasing the diastolic filling time. Pregnant women with mitral stenosis who have or develop atrial fibrillation should receive anticoagulation, similar to the nonpregnancy recommendations, but with the additional care taken regarding the choice and timing of therapy to minimize maternal and fetal risks [<a href="#rid1">1,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p>Women who develop HF despite adequate heart rate control should be treated with diuretics. Rarely, women with persistent symptoms despite medical therapy may need to be considered for a valve intervention (either valvuloplasty or mitral valve replacement) during pregnancy.</p><p>Risk assessment and management of pregnancy in women with mitral stenosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8133.html" rel="external">"Pregnancy in women with mitral stenosis"</a> and  <a class="medical medical_review" href="/z/d/html/8161.html" rel="external">"Percutaneous mitral balloon commissurotomy in adults"</a>.)</p><p class="headingAnchor" id="H10779159"><span class="h3">Pulmonic stenosis</span><span class="headingEndMark"> — </span>Isolated pulmonary valve stenosis is an uncommon congenital heart defect among women of childbearing age. Isolated pulmonary valve stenosis, even if moderate to severe, in the absence of right ventricular dysfunction is usually well tolerated during pregnancy [<a href="#rid43">43</a>]. In very rare instances, severe pulmonic stenosis may result in symptomatic right HF, particularly if there is concomitant right ventricular systolic dysfunction.</p><p>A literature review found the following rates of complications during completed (&gt;20 weeks gestation) pregnancies among women with combined repaired and unrepaired valvular pulmonic stenosis [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>With respect to the mother, there were no cardiac complications (arrhythmia, HF, or other cardiovascular events) in over 100 pregnancies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With respect to the fetus or neonate, premature delivery occurred in 16 of 110 pregnancies (14.5 percent), fetal mortality in 1 of 123 pregnancies (0.8 percent), perinatal mortality in 5 of 123 pregnancies (4.1 percent), and recurrent congenital heart disease (of any type) in offspring in 3 of 104 pregnancies (2.8 percent).</p><p></p><p>When surgical repair or balloon dilatation of congenital pulmonic valve stenosis leaves behind little or no obstruction and a competent valve, the mother can anticipate a normal pregnancy.</p><p>The outcomes are not as favorable when pulmonic stenosis is associated with other complex congenital heart lesions [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">"Pulmonic valve stenosis in adults: Management", section on 'Severe stenosis'</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Individual risk factors'</a>.)</p><p>The risk of recurrence of congenital heart disease in offspring of women with pulmonary stenosis is estimated as 3 to 6 percent. In patients with pulmonary stenosis due to autosomal dominant genetic mutations such as Noonan syndrome, the risk of the recurrence of the syndrome is 50 percent.</p><p>Percutaneous balloon valvotomy performed during pregnancy in women with symptomatic severe pulmonic stenosis can reduce pregnancy risk [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1759079984"><span class="h3">Tricuspid stenosis</span><span class="headingEndMark"> — </span>Tricuspid stenosis in women of childbearing age is very rare. Causes of tricuspid stenosis include rheumatic heart disease, congenital atresia or stenosis, right atrial tumors, carcinoid syndrome, or pacemaker lead-related fibrosis. Most cases of tricuspid rheumatic disease present with tricuspid regurgitation or a combination of regurgitation and stenosis [<a href="#rid47">47,48</a>]. Rheumatic tricuspid stenosis almost never occurs as an isolated lesion, but is generally associated with mitral valve disease and, in some cases, the aortic valve [<a href="#rid49">49,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/8136.html" rel="external">"Tricuspid stenosis", section on 'Etiology'</a>.)</p><p>Symptoms of tricuspid stenosis may first occur during pregnancy, when the cardiac output increases.</p><p>There is little experience with balloon valvotomy for tricuspid stenosis during pregnancy, but it appears to be effective in patients with refractory systemic venous congestion. Isolated balloon tricuspid valvotomy and concurrent balloon valvotomy of mitral and tricuspid valves have been successfully performed during pregnancy [<a href="#rid51">51,52</a>]. Great care must be taken to limit radiation exposure.</p><p class="headingAnchor" id="H10779166"><span class="h3">Aortic regurgitation</span><span class="headingEndMark"> — </span>In women of childbearing age, aortic regurgitation is often secondary to congenital bicuspid aortic valve disease. Less commonly, it is due to a valve damaged by endocarditis, rheumatic heart disease, or is seen in the setting of an aortopathy.</p><p>Chronic aortic regurgitation is staged according to valve anatomy, regurgitation severity, LV size and systolic function, and symptoms  (<a class="graphic graphic_table graphicRef53536" href="/z/d/graphic/53536.html" rel="external">table 3</a>) [<a href="#rid1">1</a>].</p><p>Women with asymptomatic aortic regurgitation (stage B or C1) and preserved LV systolic function tolerate pregnancy well.</p><p>A study of pregnancy outcomes in women with moderate or severe valve regurgitation reported on 40 pregnancies in women with aortic regurgitation [<a href="#rid53">53</a>]. Most women with aortic regurgitation had bicuspid aortic valves. Maternal cardiac events occurred in 5 percent of the pregnancies.</p><p>Women with severe aortic regurgitation with symptoms (stage D), LV systolic dysfunction, severe LV dilation (stage C2), or pulmonary hypertension may develop cardiac complications during pregnancy.</p><p>Women with severe aortic regurgitation with LV systolic dysfunction (LVEF &lt;30 percent) should be advised to avoid pregnancy [<a href="#rid31">31</a>]. If a woman with severe aortic regurgitation and significant LV systolic dysfunction presents early in pregnancy, we suggest termination of pregnancy followed by corrective surgery before another attempt at pregnancy. If the mother declines termination, we manage the patient medically and, as recommended by the American College of Cardiology/American Heart Association guidelines, operate only for refractory NYHA class III or IV symptoms  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 4</a>) [<a href="#rid1">1</a>].</p><p>Symptomatic patients can be treated with diuretics and, if necessary, vasodilators (eg, <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>). Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers should <strong>not</strong> be used during pregnancy because of potential harm to the fetus. (See  <a class="medical medical_review" href="/z/d/html/3507.html" rel="external">"Management of heart failure during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/8160.html" rel="external">"Natural history and management of chronic aortic regurgitation in adults", section on 'General management'</a>.)</p><p>Cardiac surgery should be avoided during pregnancy if possible. The maternal risks are similar to those in nonpregnant women, but cardiopulmonary bypass during pregnancy poses risks for the fetus. It is preferable to delay surgery, if possible, until the fetus is viable; a cesarean delivery can then be performed as part of a combined procedure [<a href="#rid12">12</a>]. (See <a class="local">'Cardiac surgery during pregnancy'</a> below.)</p><p>Pregnant women with aortic regurgitation due to Marfan syndrome are at risk for aortic dissection; the highest risk is in those with aortic root dilatation. The prophylactic use of beta blockers may minimize aortic dilation during pregnancy in such patients, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8129.html" rel="external">"Heritable thoracic aortic diseases: Pregnancy and postpartum care"</a>.)</p><p>Issues related to pregnancy in women with aortic regurgitation due to a bicuspid aortic valve are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a>.)</p><p class="headingAnchor" id="H10779173"><span class="h3">Mitral regurgitation</span><span class="headingEndMark"> — </span>Mitral regurgitation in women of childbearing age may be secondary to mitral valve prolapse, congenital heart disease (atrioventricular canal defects), or rheumatic heart disease. Mild mitral regurgitation is well tolerated during pregnancy. Moderate or severe mitral regurgitation can be tolerated during pregnancy if there is no LV systolic dysfunction or pulmonary hypertension.</p><p>In a study examining pregnancy outcomes in women with valve regurgitation, 145 pregnancies occurred in women with moderate or severe mitral regurgitation [<a href="#rid53">53</a>]. Mitral regurgitation was most commonly associated with rheumatic heart disease or mitral valve prolapse. Adverse maternal cardiac events occurred in 15 percent of pregnancies overall; however, adverse cardiac event rates were significantly lower in women who had no cardiac events prior to pregnancy, normal LV systolic function, and no evidence of pulmonary hypertension.</p><p>A study of 390 women with rheumatic mitral valve disease from the Registry of Pregnancy and Cardiac Disease (ROPAC) investigators included 117 women with isolated mitral regurgitation. HF occurred in 23 percent of the pregnancies in women with moderate or severe mitral regurgitation [<a href="#rid39">39</a>].</p><p>Women with symptomatic severe mitral regurgitation should have mitral valve repair or replacement prior to pregnancy [<a href="#rid1">1,54</a>]. If feasible, mitral valve repair is preferred to valve replacement. Women with severe mitral regurgitation and severe LV systolic dysfunction (LVEF &lt;30 percent) or significant pulmonary hypertension should be advised to avoid pregnancy [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/8138.html" rel="external">"Surgical procedures for severe chronic mitral regurgitation"</a>.)</p><p class="headingAnchor" id="H10779180"><span class="h3">Pulmonic regurgitation</span><span class="headingEndMark"> — </span>The most common cause of pulmonic regurgitation among women of childbearing age is related to congenital heart disease such as repaired tetralogy of Fallot or postvalvuloplasty in women with pulmonary stenosis. Severe pulmonic regurgitation may be associated with right ventricular dilatation and/or systolic dysfunction. Right-sided HF and atrial or ventricular tachyarrhythmias can occur during pregnancy [<a href="#rid45">45,55,56</a>].</p><p>In a study examining pregnancy outcomes in women with moderate or severe valve regurgitation, 101 pregnancies occurred in women with moderate or severe pulmonic regurgitation [<a href="#rid53">53</a>]. Most women with pulmonic regurgitation had congenital heart disease. Adverse maternal cardiac events occurred in 3 percent of the pregnancies.</p><p>Right HF risk is increased in women with moderate to severe pulmonic regurgitation who have at least one additional risk factor [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple gestation</p><p class="bulletIndent1"><span class="glyph">●</span>Branch pulmonary artery stenosis</p><p class="bulletIndent1"><span class="glyph">●</span>Right ventricular systolic dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Right ventricular hypertrophy</p><p></p><p></p><p class="headingAnchor" id="H10779187"><span class="h3">Tricuspid regurgitation</span><span class="headingEndMark"> — </span>Tricuspid regurgitation among women of childbearing age may be related to congenital heart disease (eg, Ebstein anomaly, atrioventricular canal defects), secondary to annular dilation in the setting of right ventricular volume overload lesions, or from valve damage (eg, prior infectious endocarditis). Mild tricuspid regurgitation is well tolerated during pregnancy. Women with moderate or severe tricuspid regurgitation can also do well throughout pregnancy if they have no history of cardiac events prior to pregnancy and normal ventricular function. Right-sided HF and atrial arrhythmias have been reported [<a href="#rid53">53</a>].</p><p>The risk assessment and management of pregnancy in women with Ebstein anomaly is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108790.html" rel="external">"Ebstein anomaly: Management and prognosis", section on 'Management of pregnancy'</a>.)</p><p class="headingAnchor" id="H10779194"><span class="h3">Mixed valve lesions</span><span class="headingEndMark"> — </span>Risk stratification for mixed and multivalve disease is compromised by lack of data. Expert consensus in pregnancy mirrors that for management of the nonpregnant patient with mixed and multivalve disease. The most hemodynamically significant valve lesion will generally be the predominant influence determining risk and care for patients during pregnancy. In the Canadian study of pregnancy outcomes in women with valve regurgitation, adverse maternal cardiac events occurred in 27 percent of the 71 pregnancies in women with moderate or severe multivalve regurgitation [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H10779202"><span class="h3">Prosthetic mechanical valves</span><span class="headingEndMark"> — </span>The management of pregnant women with prosthetic mechanical valves is complicated due to the increased risk of prosthetic valve thrombosis and thromboembolism related to the relative hypercoagulable state and difficulty managing anticoagulation during pregnancy. Women with older mechanical valves (ball-and-cage valves, single tilting disc), mechanical valves in the mitral valve position, multiple mechanical valves, arrhythmias, and those with a history of thromboembolic events are at higher risk of valve thrombosis than others. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8126.html" rel="external">"Management of antithrombotic therapy for a prosthetic heart valve during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H10779216"><span class="h1">ANTENATAL CARDIOLOGY FOLLOW-UP</span><span class="headingEndMark"> — </span>Women with low-risk valvular heart disease (VHD) can often be managed by their local general cardiology and obstetric team. Reassurance is important to prevent anxiety and overtesting [<a href="#rid57">57</a>].</p><p>Women with moderate- or high-risk VHD should be followed at a center with cardiologists, high-risk obstetricians (maternal fetal medicine specialists), and obstetric anesthesiologists with experience in VHD and pregnancy.</p><p>The frequency of follow-up visits during pregnancy is dependent on the type and severity of the VHD. Typically, women at low risk are seen by their cardiologist for an early antenatal visit (first trimester), at the time of the peak hemodynamic load of pregnancy (third trimester), and postpartum [<a href="#rid31">31</a>]. Women with moderate or severe valve lesions are followed more frequently. Follow-up should include periodic transthoracic echocardiograms. (See <a class="local">'Modified WHO classification'</a> above.)</p><p class="headingAnchor" id="H339822066"><span class="h1">CARDIAC SURGERY DURING PREGNANCY</span><span class="headingEndMark"> — </span>In appropriate candidates, surgery prior to pregnancy can decrease pregnancy risk. Successful cardiac surgery can improve fertility and decrease the fetal risks in women with cyanotic heart disease, enable the mother to better tolerate the physiologic changes of pregnancy, and potentially provide long-term benefits to the subsequent health of mother and child [<a href="#rid12">12</a>].</p><p>When possible, cardiac surgery during pregnancy should be avoided. The maternal risks are approximately the same as those in nonpregnant women [<a href="#rid12">12,58,59</a>], but cardiopulmonary bypass during pregnancy incurs risk for the fetus related to nonpulsatile blood flow and reduced uteroplacental flow [<a href="#rid12">12,58-61</a>]. If cardiopulmonary bypass is needed, high blood flow (2.5 L/min per m<sup>2</sup>) and mean arterial blood pressure greater than 70 mmHg are recommended to maximize placental perfusion. Rewarming after deep hypothermia can result in preterm labor and delivery [<a href="#rid12">12,59,62-64</a>].</p><p>The following maternal and fetal outcomes were observed after surgery involving cardiopulmonary bypass during pregnancy:</p><p class="bulletIndent1"><span class="glyph">●</span>In 21 pregnant women undergoing cardiothoracic surgery at the Mayo Clinic between 1976 and 2009, there was one early maternal death that occurred during emergency surgery in a woman with an aortic valve prosthesis thrombosis and severe LV dysfunction [<a href="#rid12">12</a>]. Of the 14 women who delivered after surgery (excluding women with cesarean delivery immediately prior to surgery), there were three fetal losses, three preterm deliveries, seven term infants, and one patient lost to follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal and neonatal mortality has been reported to be between 19 and 33 percent [<a href="#rid12">12,58,59,61</a>].</p><p></p><p>If a woman presents early in pregnancy with a severe valve disease requiring surgery, we recommend considering termination of pregnancy followed by appropriate intervention before another attempt at pregnancy. (See  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Pregnancy termination'</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Modified WHO classification'</a>.)</p><p>If the mother declines termination, we manage the patient medically and operate only for severe, intractable symptoms as recommended by the American Heart Association/American College of Cardiology valve guidelines [<a href="#rid1">1</a>]. If surgery can be safely delayed until the fetus is viable, a cesarean delivery can then be performed as part of a combined procedure.</p><p>During surgery, women can be positioned in the left lateral position to displace the uterus and minimize aorto-caval compression depending on the stage of the gravid uterus. The fetal heart rate should be monitored continuously when surgery is performed later in gestation (&gt;24 weeks). Fetal bradycardia often responds to an increase in pump flow rate. Prolonged fetal bradycardia (less than 80 beats per minute) that is unresponsive to increased pump flow rates is an indication for cesarean delivery if the fetus is at a viable gestational age. (See  <a class="medical medical_review" href="/z/d/html/6775.html" rel="external">"Anesthesia for nonobstetric surgery during pregnancy"</a>.)</p><p>Animal studies and case reports in pregnant women suggest that hypothermia to 25°C does not adversely affect the fetus. However, rewarming may increase both uterine activity and the risk of preterm labor. Although moderate hypothermia (32°C) is probably safe, the effects on the fetus have not been well studied.</p><p>Cesarean delivery has been successfully performed while the mother was on cardiopulmonary bypass [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H674174547"><span class="h1">LABOR AND DELIVERY MANAGEMENT</span></p><p class="headingAnchor" id="H483046934"><span class="h2">Location and type of delivery</span><span class="headingEndMark"> — </span>In general, women with low-risk valve lesions can deliver at their local hospital. Women with moderate- or high-risk valvular heart disease (VHD), including those with prosthetic valves, should deliver at a center with expertise in pregnancy and heart disease [<a href="#rid31">31</a>]. In women with high-risk lesions, a labor and delivery plan should be prepared in advance and circulated to all members of the health care team. All women should be evaluated by the obstetric anesthesia team prior to delivery. Women with high-risk lesions should have maternal cardiac monitoring with continuous telemetry during labor and delivery. Intra-arterial blood pressure monitoring may be useful in women with severe aortic stenosis or other high-risk valve lesions.</p><p>We suggest vaginal delivery with appropriate analgesia/anesthesia and minimization of Valsalva (ie, a "cardiac" delivery) in women with VHD. Some groups advocate for planned cesarean delivery in women with severe aortic stenosis. (See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy", section on 'Mode of delivery'</a>.)</p><p>Further details regarding the anesthetic and obstetric management of labor and vaginal delivery in women with high-risk cardiac disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4446.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: General considerations"</a> and  <a class="medical medical_review" href="/z/d/html/93919.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: Specific lesions"</a>.)</p><p>Medication safety during lactation should be reviewed prior to hospital discharge for women who are breastfeeding [<a href="#rid66">66</a>]. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trystKLNkAhaR%2FcduMJFFebszM73aaFBm717nqYa%2FpVDsg%3D%3D&amp;TOPIC_ID=97124" target="_blank">LactMed</a> is a useful resource.</p><p class="headingAnchor" id="H674174553"><span class="h2">Endocarditis prophylaxis</span><span class="headingEndMark"> — </span>Routine antimicrobial prophylaxis for infective endocarditis is not recommended for most women (with or without heart disease) during pregnancy and delivery [<a href="#rid11">11,67,68</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotic prophylaxis to reduce the risk of postpartum endometritis is routinely given prior to all cesarean deliveries  (<a class="graphic graphic_table graphicRef87200" href="/z/d/graphic/87200.html" rel="external">table 5</a>), and will provide protection against endocarditis as well. (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal delivery is not an indication for routine antibiotic prophylaxis, as the rate of bacteremia and infection associated with this procedure is low [<a href="#rid11">11,68</a>]. However, for selected patients deemed at highest risk for adverse outcomes from endocarditis (eg, those with prosthetic heart valves, prior infective endocarditis, or unrepaired cyanotic congenital heart disease) some clinicians administer antibiotic prophylaxis (using the same regimens used to prophylax against endometritis prior to cesarean delivery) prior to vaginal delivery (eg, 30 to 60 minutes before the estimated time of delivery) [<a href="#rid69">69,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p>Infective endocarditis is a rare and potentially life-threatening complication of pregnancy, although rates have not been well defined. In a study of 299 blood cultures obtained from 83 women without signs of infection at 0 to 30 minutes after vaginal delivery, three patients (3.6 percent) had a single positive blood culture, and all were likely due to specimen contamination [<a href="#rid71">71</a>]. Rare case reports have described bacterial endocarditis following vaginal delivery [<a href="#rid71">71,72</a>]. In a 2014 review of the literature, 90 cases of infective endocarditis in pregnancy or postpartum were identified. The most common risk factors associated with infective endocarditis were intravenous drug use (14 percent), congenital heart disease (12 percent), and rheumatic heart disease (12 percent). Maternal mortality was 11 percent. However, most of the data came from individual case reports and are subject to publication bias [<a href="#rid73">73</a>].</p><p>In patients with established or suspected infection that could cause bacteremia (such as chorioamnionitis or pyelonephritis), the underlying infection should be treated in the usual fashion. (See  <a class="medical medical_review" href="/z/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a> and  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy", section on 'Acute pyelonephritis'</a> and  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures", section on 'Timely treatment of infection'</a>.)</p><p class="headingAnchor" id="H674174559"><span class="h1">POSTPARTUM MANAGEMENT</span><span class="headingEndMark"> — </span>The frequency of postpartum monitoring will be dictated by the type and severity of the valve lesions and symptom status. The hemodynamic changes of pregnancy may not return to normal for as long as six months following delivery [<a href="#rid31">31</a>]. During this period, especially early postpartum, there is a continued risk of developing cardiac and obstetric complications. In view of the ongoing risks, we suggest monitoring women early (6 to 10 weeks) and late after delivery (up to four to six months). These visits also provide an opportunity to adjust medications to prepregnancy dose scheduling if compatible with lactation [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H847843242"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122280.html" rel="external">"Society guideline links: Congenital heart disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118887.html" rel="external">"Society guideline links: Management of cardiovascular diseases during pregnancy"</a>.)</p><p class="headingAnchor" id="H10779262"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The hemodynamic changes of pregnancy can result in cardiac decompensation in women with severe valvular heart disease (VHD) lesions. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When possible, women with VHD should have a preconception risk assessment and counseling. For women who have not had preconception counseling, a complete risk evaluation should occur at the first antenatal visit. (See <a class="local">'Preconception or initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most women with mild forms of VHD will do well throughout pregnancy. (See <a class="local">'Lesion specific risks and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with mitral stenosis, even mild mitral stenosis, are at risk for pregnancy-related complications. (See <a class="local">'Mitral stenosis'</a> above and  <a class="medical medical_review" href="/z/d/html/8133.html" rel="external">"Pregnancy in women with mitral stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with mechanical heart valves are at high risk for pregnancy-related complications. (See <a class="local">'Prosthetic mechanical valves'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with severe mitral stenosis, symptomatic severe aortic stenosis, and VHD associated with severe left ventricular systolic dysfunction or significant pulmonary hypertension should be advised to avoid pregnancy due to the high risk of cardiovascular and fetal complications. (See <a class="local">'Modified WHO classification'</a> above and <a class="local">'Aortic stenosis'</a> above and <a class="local">'Mitral stenosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with moderate- or high-risk VHD should be referred to a center with experience in pregnancy and heart disease. (See <a class="local">'Antenatal cardiology follow-up'</a> above and <a class="local">'Specific lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, vaginal delivery with appropriate analgesia/anesthesia and minimization of Valsalva (ie, a "cardiac" delivery) is preferred in women with VHD. (See <a class="local">'Labor and delivery management'</a> above.)</p><p></p><p class="headingAnchor" id="H467023410"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jacob A Udell, MD, MPH, FRCPC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Kovacs AH, Harrison JL, Colman JM, et al. Pregnancy and contraception in congenital heart disease: what women are not told. J Am Coll Cardiol 2008; 52:577.</a></li><li><a class="nounderline abstract_t">Bamfo JE, Kametas NA, Nicolaides KH, Chambers JB. Maternal left ventricular diastolic and systolic long-axis function during normal pregnancy. Eur J Echocardiogr 2007; 8:360.</a></li><li><a class="nounderline abstract_t">Waksmonski CA. Cardiac imaging and functional assessment in pregnancy. Semin Perinatol 2014; 38:240.</a></li><li><a class="nounderline abstract_t">Jimenez-Juan L, Krieger EV, Valente AM, et al. Cardiovascular magnetic resonance imaging predictors of pregnancy outcomes in women with coarctation of the aorta. Eur Heart J Cardiovasc Imaging 2014; 15:299.</a></li><li><a class="nounderline abstract_t">Ducas RA, Elliott JE, Melnyk SF, et al. Cardiovascular magnetic resonance in pregnancy: insights from the cardiac hemodynamic imaging and remodeling in pregnancy (CHIRP) study. J Cardiovasc Magn Reson 2014; 16:1.</a></li><li><a class="nounderline abstract_t">Lui GK, Silversides CK, Khairy P, et al. Heart rate response during exercise and pregnancy outcome in women with congenital heart disease. Circulation 2011; 123:242.</a></li><li><a class="nounderline abstract_t">Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56:1247.</a></li><li><a class="nounderline abstract_t">Kampman MA, Balci A, van Veldhuisen DJ, et al. N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. Eur Heart J 2014; 35:708.</a></li><li><a class="nounderline abstract_t">Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native valves. J Am Coll Cardiol 2005; 46:223.</a></li><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39:3165.</a></li><li><a class="nounderline abstract_t">John AS, Gurley F, Schaff HV, et al. Cardiopulmonary bypass during pregnancy. Ann Thorac Surg 2011; 91:1191.</a></li><li><a class="nounderline abstract_t">Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves. J Am Coll Cardiol 2005; 46:403.</a></li><li><a class="nounderline abstract_t">Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335:407.</a></li><li><a class="nounderline abstract_t">Badduke BR, Jamieson WR, Miyagishima RT, et al. Pregnancy and childbearing in a population with biologic valvular prostheses. J Thorac Cardiovasc Surg 1991; 102:179.</a></li><li><a class="nounderline abstract_t">Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994; 71:196.</a></li><li><a class="nounderline abstract_t">North RA, Sadler L, Stewart AW, et al. Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation 1999; 99:2669.</a></li><li><a class="nounderline abstract_t">Jamieson WR, Miller DC, Akins CW, et al. Pregnancy and bioprostheses: influence on structural valve deterioration. Ann Thorac Surg 1995; 60:S282.</a></li><li><a class="nounderline abstract_t">Salazar E, Espinola N, Román L, Casanova JM. Effect of pregnancy on the duration of bovine pericardial bioprostheses. Am Heart J 1999; 137:714.</a></li><li><a class="nounderline abstract_t">Avila WS, Rossi EG, Grinberg M, Ramires JA. Influence of pregnancy after bioprosthetic valve replacement in young women: a prospective five-year study. J Heart Valve Dis 2002; 11:864.</a></li><li><a class="nounderline abstract_t">Horstkotte D, Lengyel M, Mistiaen WP, et al. Recommendations for reporting morbid events after heart valve surgery. J Heart Valve Dis 2005; 14:1.</a></li><li><a class="nounderline abstract_t">El SF, Hassan W, Latroche B, et al. Pregnancy has no effect on the rate of structural deterioration of bioprosthetic valves: long-term 18-year follow up results. J Heart Valve Dis 2005; 14:481.</a></li><li><a class="nounderline abstract_t">Aboud A, Charitos EI, Fujita B, et al. Long-Term Outcomes of Patients Undergoing the Ross Procedure. J Am Coll Cardiol 2021; 77:1412.</a></li><li><a class="nounderline abstract_t">Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.</a></li><li><a class="nounderline abstract_t">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.</a></li><li><a class="nounderline abstract_t">Silversides CK, Grewal J, Mason J, et al. Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study. J Am Coll Cardiol 2018; 71:2419.</a></li><li><a class="nounderline abstract_t">Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.</a></li><li><a class="nounderline abstract_t">Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006; 113:517.</a></li><li><a class="nounderline abstract_t">Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001; 37:893.</a></li><li><a class="nounderline abstract_t">Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation 2002; 105:2179.</a></li><li><a class="nounderline abstract_t">European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.</a></li><li><a class="nounderline abstract_t">Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart 2006; 92:1520.</a></li><li><a class="nounderline abstract_t">Silversides CK, Colman JM, Sermer M, et al. Early and intermediate-term outcomes of pregnancy with congenital aortic stenosis. Am J Cardiol 2003; 91:1386.</a></li><li><a class="nounderline abstract_t">Yap SC, Drenthen W, Pieper PG, et al. Risk of complications during pregnancy in women with congenital aortic stenosis. Int J Cardiol 2008; 126:240.</a></li><li><a class="nounderline abstract_t">McKellar SH, MacDonald RJ, Michelena HI, et al. Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events. Am J Cardiol 2011; 107:96.</a></li><li><a class="nounderline abstract_t">Orwat S, Diller GP, van Hagen IM, et al. Risk of Pregnancy in Moderate and Severe Aortic Stenosis: From the Multinational ROPAC Registry. J Am Coll Cardiol 2016; 68:1727.</a></li><li><a class="nounderline abstract_t">Ducas RA, Javier DA, D'Souza R, et al. Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis. Heart 2020; 106:512.</a></li><li><a class="nounderline abstract_t">Silversides CK, Colman JM, Sermer M, Siu SC. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol 2003; 91:1382.</a></li><li><a class="nounderline abstract_t">van Hagen IM, Thorne SA, Taha N, et al. Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease. Circulation 2018; 137:806.</a></li><li><a class="nounderline abstract_t">de Souza JA, Martinez EE Jr, Ambrose JA, et al. Percutaneous balloon mitral valvuloplasty in comparison with open mitral valve commissurotomy for mitral stenosis during pregnancy. J Am Coll Cardiol 2001; 37:900.</a></li><li><a class="nounderline abstract_t">Sivadasanpillai H, Srinivasan A, Sivasubramoniam S, et al. Long-term outcome of patients undergoing balloon mitral valvotomy in pregnancy. Am J Cardiol 2005; 95:1504.</a></li><li><a class="nounderline abstract_t">Gamra H, Ben-Farhat M, Betbout F, et al. Long term outcome of balloon mitral commissurotomy during pregnancy: a prospective physical and mental evaluation of babies. EuroIntervention 2006; 2:302.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Non-cardiac complications during pregnancy in women with isolated congenital pulmonary valvar stenosis. Heart 2006; 92:1838.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.</a></li><li><a class="nounderline abstract_t">Greutmann M, Von Klemperer K, Brooks R, et al. Pregnancy outcome in women with congenital heart disease and residual haemodynamic lesions of the right ventricular outflow tract. Eur Heart J 2010; 31:1764.</a></li><li><a class="nounderline abstract_t">Presbitero P, Prever SB, Brusca A. Interventional cardiology in pregnancy. Eur Heart J 1996; 17:182.</a></li><li><a class="nounderline abstract_t">Hauck AJ, Freeman DP, Ackermann DM, et al. Surgical pathology of the tricuspid valve: a study of 363 cases spanning 25 years. Mayo Clin Proc 1988; 63:851.</a></li><li><a class="nounderline abstract_t">Daniels SJ, Mintz GS, Kotler MN. Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations. Am J Cardiol 1983; 51:492.</a></li><li><a class="nounderline abstract_t">Roguin A, Rinkevich D, Milo S, et al. Long-term follow-up of patients with severe rheumatic tricuspid stenosis. Am Heart J 1998; 136:103.</a></li><li><a class="nounderline abstract_t">Sharma S, Loya YS, Desai DM, Pinto RJ. Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up. Am Heart J 1997; 133:64.</a></li><li><a class="nounderline abstract_t">Gamra H, Betbout F, Ayari M, et al. Recurrent miscarriages as an indication for percutaneous tricuspid valvuloplasty during pregnancy. Cathet Cardiovasc Diagn 1997; 40:283.</a></li><li><a class="nounderline abstract_t">Bahl VK, Chandra S, Mishra S. Concurrent balloon dilatation of mitral and tricuspid stenosis during pregnancy using an Inoue balloon. Int J Cardiol 1997; 59:199.</a></li><li><a class="nounderline abstract_t">Pfaller B, Dave Javier A, Grewal J, et al. Risk Associated With Valvular Regurgitation During Pregnancy. J Am Coll Cardiol 2021; 77:2656.</a></li><li><a class="nounderline abstract_t">De Santo LS, Romano G, Della Corte A, et al. Mitral mechanical replacement in young rheumatic women: analysis of long-term survival, valve-related complications, and pregnancy outcomes over a 3707-patient-year follow-up. J Thorac Cardiovasc Surg 2005; 130:13.</a></li><li><a class="nounderline abstract_t">Meijer JM, Pieper PG, Drenthen W, et al. Pregnancy, fertility, and recurrence risk in corrected tetralogy of Fallot. Heart 2005; 91:801.</a></li><li><a class="nounderline abstract_t">Metz TD, Hayes SA, Garcia CY, Yetman AT. Impact of pregnancy on the cardiac health of women with prior surgeries for pulmonary valve anomalies. Am J Obstet Gynecol 2013; 209:370.e1.</a></li><li><a class="nounderline abstract_t">Windram JD, Colman JM, Wald RM, et al. Valvular heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 2014; 28:507.</a></li><li><a class="nounderline abstract_t">Weiss BM, von Segesser LK, Alon E, et al. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. Am J Obstet Gynecol 1998; 179:1643.</a></li><li><a class="nounderline abstract_t">Parry AJ, Westaby S. Cardiopulmonary bypass during pregnancy. Ann Thorac Surg 1996; 61:1865.</a></li><li><a class="nounderline abstract_t">Strickland RA, Oliver WC Jr, Chantigian RC, et al. Anesthesia, cardiopulmonary bypass, and the pregnant patient. Mayo Clin Proc 1991; 66:411.</a></li><li><a class="nounderline abstract_t">Chambers CE, Clark SL. Cardiac surgery during pregnancy. Clin Obstet Gynecol 1994; 37:316.</a></li><li><a class="nounderline abstract_t">Tripp HF, Stiegel RM, Coyle JP. The use of pulsatile perfusion during aortic valve replacement in pregnancy. Ann Thorac Surg 1999; 67:1169.</a></li><li><a class="nounderline abstract_t">Goldstein I, Jakobi P, Gutterman E, Milo S. Umbilical artery flow velocity during maternal cardiopulmonary bypass. Ann Thorac Surg 1995; 60:1116.</a></li><li><a class="nounderline abstract_t">Pomini F, Mercogliano D, Cavalletti C, et al. Cardiopulmonary bypass in pregnancy. Ann Thorac Surg 1996; 61:259.</a></li><li><a class="nounderline abstract_t">Martin MC, Pernoll ML, Boruszak AN, et al. Cesarean section while on cardiac bypass: report of a case. Obstet Gynecol 1981; 57:41S.</a></li><li class="breakAll">LactMed. Available at: https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm (Accessed on June 15, 2017).</li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017.</a></li><li><a class="nounderline abstract_t">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</a></li><li><a class="nounderline abstract_t">Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2017; 135:e50.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstet Gynecol 2018; 132:e103.</a></li><li><a class="nounderline abstract_t">Sugrue D, Blake S, Troy P, MacDonald D. Antibiotic prophylaxis against infective endocarditis after normal delivery--is it necessary? Br Heart J 1980; 44:499.</a></li><li><a class="nounderline abstract_t">Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 1994; 89:2673.</a></li><li><a class="nounderline abstract_t">Kebed KY, Bishu K, Al Adham RI, et al. Pregnancy and postpartum infective endocarditis: a systematic review. Mayo Clin Proc 2014; 89:1143.</a></li></ol></div><div id="topicVersionRevision">Topic 97124 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687254" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pregnancy and contraception in congenital heart disease: what women are not told.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321800" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Maternal left ventricular diastolic and systolic long-axis function during normal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037513" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cardiac imaging and functional assessment in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037808" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiovascular magnetic resonance imaging predictors of pregnancy outcomes in women with coarctation of the aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24387349" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiovascular magnetic resonance in pregnancy: insights from the cardiac hemodynamic imaging and remodeling in pregnancy (CHIRP) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220738" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Heart rate response during exercise and pregnancy outcome in women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883932" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : B-type natriuretic peptide in pregnant women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334717" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16022946" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Valvular heart disease and pregnancy part I: native valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165544" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21440145" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiopulmonary bypass during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053950" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Valvular heart disease and pregnancy: part II: prosthetic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676934" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prosthetic heart valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1865693" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pregnancy and childbearing in a population with biologic valvular prostheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130033" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcome of pregnancy in women with valve prostheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10338461" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term survival and valve-related complications in young women with cardiac valve replacements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646173" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pregnancy and bioprostheses: influence on structural valve deterioration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10097235" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of pregnancy on the duration of bovine pericardial bioprostheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479290" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Influence of pregnancy after bioprosthetic valve replacement in young women: a prospective five-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15700427" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recommendations for reporting morbid events after heart valve surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116874" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pregnancy has no effect on the rate of structural deterioration of bioprosthetic valves: long-term 18-year follow up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33736823" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-Term Outcomes of Patients Undergoing the Ross Procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386139" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk and predictors for pregnancy-related complications in women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479246" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prospective multicenter study of pregnancy outcomes in women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29793631" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584777" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predictors of pregnancy complications in women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449731" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pregnancy outcomes in women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693767" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effect of valvular heart disease on maternal and fetal outcome of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994252" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873418" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973809" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risks of contraception and pregnancy in heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767444" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early and intermediate-term outcomes of pregnancy with congenital aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482293" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of complications during pregnancy in women with congenital aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146694" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737738" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk of Pregnancy in Moderate and Severe Aortic Stenosis: From the Multinational ROPAC Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054673" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767443" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiac risk in pregnant women with rheumatic mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29459466" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693768" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Percutaneous balloon mitral valvuloplasty in comparison with open mitral valve commissurotomy for mitral stenosis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950584" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term outcome of patients undergoing balloon mitral valvotomy in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755305" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long term outcome of balloon mitral commissurotomy during pregnancy: a prospective physical and mental evaluation of babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818485" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Non-cardiac complications during pregnancy in women with isolated congenital pulmonary valvar stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572244" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outcome of pregnancy in women with congenital heart disease: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511325" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pregnancy outcome in women with congenital heart disease and residual haemodynamic lesions of the right ventricular outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8732370" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Interventional cardiology in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3045434" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Surgical pathology of the tricuspid valve: a study of 363 cases spanning 25 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823865" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9665226" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term follow-up of patients with severe rheumatic tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006292" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062725" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recurrent miscarriages as an indication for percutaneous tricuspid valvuloplasty during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158176" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Concurrent balloon dilatation of mitral and tricuspid stenosis during pregnancy using an Inoue balloon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34045022" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk Associated With Valvular Regurgitation During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999035" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mitral mechanical replacement in young rheumatic women: analysis of long-term survival, valve-related complications, and pregnancy outcomes over a 3707-patient-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894783" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pregnancy, fertility, and recurrence risk in corrected tetralogy of Fallot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685079" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of pregnancy on the cardiac health of women with prior surgeries for pulmonary valve anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813453" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Valvular heart disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855611" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651812" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cardiopulmonary bypass during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2013992" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Anesthesia, cardiopulmonary bypass, and the pregnant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8033446" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiac surgery during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10320278" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The use of pulsatile perfusion during aortic valve replacement in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574965" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Umbilical artery flow velocity during maternal cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561577" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cardiopulmonary bypass in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7243121" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cesarean section while on cardiac bypass: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7243121" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cesarean section while on cardiac bypass: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28298458" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446442" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28082385" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Management of Pregnancy in Patients With Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30134425" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7437187" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Antibiotic prophylaxis against infective endocarditis after normal delivery--is it necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205680" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24997091" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pregnancy and postpartum infective endocarditis: a systematic review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
